1. New Anticoagulants for the Prevention of Deep Venous Thrombosis

   • Stavros Apostolakis
   • Eduard Shantsila
   • Gregory Y. H. Lip

   Commentary 17 September 2012 Pages: 793 - 795

2. Economic Evaluation and Cost-Effectiveness Thresholds

   • John A. Vernon
   • Robert Goldberg
   • Joseph Golec

   Current Opinion 17 September 2012 Pages: 797 - 806

   

3. Budget-Impact Analyses

   • Ewa Orlewska
   • Laszlo Gulácsi

   Review Article 17 September 2012 Pages: 807 - 827

   

4. A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting

   • Laura McCullagh
   • Lesley Tilson
   • Michael Barry

   Original Research Article 17 September 2012 Pages: 829 - 846

   

5. An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK

   • Ágnes Benedict
   • David A. Cameron
   • Stephen E. Jones

   Original Research Article 17 September 2012 Pages: 847 - 859

   

6. 30 Years of Pharmaceutical Cost-Utility Analyses

   • Peter J. Neumann
   • Chi-Hui Fang
   • Joshua T. Cohen

   Original Research Article 17 September 2012 Pages: 861 - 872

   

7. Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective

   • Peng Liubao
   • Wan Xiaomin
   • Cao Junhua

   Original Research Article 17 September 2012 Pages: 873 - 886